Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Pietro QuaglinoH M PrinceR CowanM VermeerE PapadavidM BagotO ServitjieE BertiEmmanuella GuenovaR StadlerC QuerfeldA M BusschotsE HodakA PatsatsiJ SanchesM MauleJ YooM KevinP FavaS RiberoL ZocchiM RubattoM T FierroU WehkampM MarshalkoC MitteldorfO AkilovP Ortiz-RomeroT EstrachL VakevaP A EnzM WobserM BayneC JonakM RubetaA ForbesA BatesM BattistellaR Amel-KashipazB VydianathA CombaliaE GeorgiouE HaubenE K HongM JostR KnoblerI Amitay-LaishD MiyashiroJ Cury-MartinsX MartinezC MuniesaH Prag-NavehA StratigosV NikolaouK QuintC Ram-WolffK RiegerR StranzenbachÁ SzepesiS Alberti-ViolettiE FelicityL CerroniW KempfS WhittakerR WillemzeY KimJ J ScarisbrickPublished in: The British journal of dermatology (2021)
Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.